Hostname: page-component-cd9895bd7-gxg78 Total loading time: 0 Render date: 2024-12-26T09:08:41.317Z Has data issue: false hasContentIssue false
  • English
  • Français

Opportunities and Challenges in Translational Research: The Development of Photodynamic Therapy and Anti-Vascular Endothelial Growth Factor Drugs

Published online by Cambridge University Press:  21 April 2021

Christina Kaiser Marko  and
Joan W. Miller
Get access Rights & Permissions [Opens in a new window]

Abstract

The development of photodynamic therapy and anti-vascular endothelial growth factor agents have revolutionized the treatment of retinal diseases, transforming the retina subspecialty by ushering in an age of pharmacological treatments for a wide range of diseases, including age-related macular degeneration (AMD).

Keywords

OphthalmologyMacular DegenerationAMDVEGFPDTIndustryacademia
Type
Symposium Articles
Information
Journal of Law, Medicine & Ethics , Volume 49 , Issue 1: Public Sector and Non-Profit Contributions to Drug Development: Historical Scope, Opportunities, and Challenges , Spring 2021 , pp. 19 - 24
Copyright
© 2021 The Author(s)

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Macular Photocoagulation Study Group, “Laser Photocoagulation of Subfoveal Neovascular Lesions in Age-Related Macular Degeneration: Results of a Randomized Clinical Trial”, Archives of Ophthalmology 109, no. 9 (1991): 1220–1231.CrossRefGoogle Scholar
Miller, J.W., et al., “Photodynamic Therapy of Experimental Choroidal Neovascularization Using Lipoprotein-Delivered Benzoporphyrin”, Archives of Ophthalmology 113, no. 6 (1995): 810–818; M. Kramer, et al., “Liposomal Benzoporphyrin Derivative Verteporfin Photodynamic Therapy: Selective Treatment of Choroidal Neovascularization in Monkeys”, Ophthalmology 103, no. 3 (1996): 427-438; D. Husain, et al., “Intravenous Infusion of Liposomal Benzoporphyrin Derivative for Photo-dynamic Therapy of Experimental Choroidal Neovasculariza-tion”, Archives of Ophthalmology 114, no. 8 (1996): 978-985.CrossRefGoogle ScholarPubMed
Verteporfin Roundtable 2000 and 2001 Participants et al., “Guidelines for Using Verteporfin (Visudyne) in Photody-namic Therapy to Treat Choroidal Neovascularization Due to Age-Related Macular Degeneration and Other Causes”, Retina 22, no. 1 (2002): 6–18.CrossRefGoogle Scholar
TAP Study Group, “Photodynamic Therapy of Subfoveal Cho-roidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: One-Year Results of 2 Randomized Clinical Trials”, Archives of Ophthalmology 117, no. 10 (1999): 1329–1345; N. M. Bressler, “Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group Photodynamic Therapy of Subfoveal Choroidal Neovascularization in Age-Related Macular Degeneration with Verteporfin: Two-Year Results of 2 Randomized Clinical Trials-Tap Report 2”, Archives of Ophthalmology 119, no. 2 (2001): 198-207; Verteporfin in Photodynamic Therapy Study, “Photodynamic Therapy of Subfoveal Choroidal Neo-vascularization in Pathologic Myopia with Verteporfin: 1-Year Results of a Randomized Clinical Trial — VIP Report no. 1”, Ophthalmology 108, no. 5 (2001): 841-852; Verteporfin In Photodynamic Therapy Study, “Verteporfin Therapy of Sub-foveal Choroidal Neovascularization in Age-Related Macular Degeneration: Two-Year Results of a Randomized Clinical Trial Including Lesions with Occult with no Classic Choroidal Neovascularization — Verteporfin in Photodynamic Therapy Report 2.” American Journal of Ophthalmology 131, no. 5 (2001): 541-560.CrossRefGoogle Scholar
Michaelson, I. C., “The Mode of Development of the Vascular System of the Retina, with Some Observations on its Significance for Certain Retinal Diseases”, Transactions of the Ophthalmological Societies of the United Kingdom 68 (1948): 137–180.Google Scholar
Gimbrone, M. A. Jr., et al., “Tumor Dormancy in Vivo by Prevention of Neovascularization”, Journal of Experimental Medicine 136, no. 2 (1972): 261–276.CrossRefGoogle ScholarPubMed
Folkman, J., “Tumor Angiogenesis: Therapeutic Implications”, New England Journal of Medicine 285, no. 21 (1971): 1182–1186.Google ScholarPubMed
Klagsbrun, M. M. and Moses, M.A., “Obituary: M. Judah Folk-man (1933-2008)”, Nature 451, no. 7180 (2008): 781.CrossRefGoogle Scholar
Leung, D. W., et al., “Vascular Endothelial Growth Factor is a Secreted Angiogenic Mitogen”, Science 246, no. 4935 (1989): 1306–1309.CrossRefGoogle ScholarPubMed
Keck, P. J., et al., “Vascular Permeability Factor, An Endothelial Cell Mitogen Related to PDGF”, Science 246, no. 4935 (1989): 1309–1312.CrossRefGoogle ScholarPubMed
Senger, D. R., et al., “Tumor Cells Secrete a Vascular Permeability Factor that Promotes Accumulation of Ascites Fluid”, Science 219, no. 4587 (1983): 983–985.CrossRefGoogle ScholarPubMed
Miller, J. W. et al., “Vascular Endothelial Growth Factor/Vascular Permeability Factor is Temporally and Spatially Correlated with Ocular Angiogenesis in a Primate Model”, The American Journal of Pathology 145, no. 3 (1994): 574–584.Google Scholar
Aiello, L. P., et al., “Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal Disorders”, New England Journal of Medicine 331, no. 22 (1994): 1480–1487.CrossRefGoogle ScholarPubMed
Adamis, A. P. et al., “Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia-Associated Iris Neovascular-ization in a Nonhuman Primate”, Archives of Ophthalmology 114, no. 1 (1996): 66–71.CrossRefGoogle Scholar
Tolentino, M. J. et al., “Vascular Endothelial Growth Factor is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman Primate”, Archives of Ophthalmology 114, no. 8 (1996): 964–970.CrossRefGoogle Scholar
Engler, C. B. et al., “Interferon Alpha-2a Treatment of Patients with Subfoveal Neovascular Macular Degeneration: A Pilot Investigation”, Acta Ophthalmologica 71, no. 1 (1993): 27–31; C. Ross et al., “IFN-Alpha Antibodies in Patients with Age-Related Macular Degeneration Treated with Recombinant Human IFN-Alpha2a”, Journal oflnterferon & Cytokine Research 22, no. 4 (2002): 421-426.CrossRefGoogle ScholarPubMed
Gragoudas, E. S. et al., “Pegaptanib for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 351, no. 27 (2004): 2805–2816.CrossRefGoogle ScholarPubMed
Miller, J. W. et al., “Photodynamic Therapy with Vertepor-fin for Choroidal Neovascularization Caused by Age-Related Macular Degeneration: Results of a Single Treatment in a Phase 1 and 2 Study”, Archives of Ophthalmology 117, no. 9 (1999): 1161–1173.CrossRefGoogle Scholar
Rosenfeld, P. J. et al., “Ranibizumab for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 355, no. 14 (2006): 1419–1431.CrossRefGoogle ScholarPubMed
Brown, D. M. et al., “Ranibizumab Versus Verteporfin for Neo-vascular Age-Related Macular Degeneration”, New England Journal of Medicine 355, no. 14 (2006): 1432–1444.CrossRefGoogle Scholar
Rosenfeld, P. J., Moshfeghi, A.A., and Puliafito, C.A., “Optical Coherence Tomography Findings after an Intravitreal Injection of Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration”, Ophthalmic Surgical Lasers Imaging 36, no. 4 (2005): 331–335.CrossRefGoogle ScholarPubMed
CATT Research Group et al., “Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration”, New England Journal of Medicine 364, no. 20 (2011): 1897–1908.CrossRefGoogle Scholar
Comparison of Age-related Macular Degeneration Treatments Trials Research Group et al., “Ranibizumab and Bevacizumab for Treatment of Neovascular Age-Related Macular Degeneration: Two-Year Results”, Ophthalmology 119, no. 7 (2012): 1388–1398.CrossRefGoogle Scholar
CATT Research Group et al., supra note 22; Id.Google Scholar
IVAN Study Investigators et al., “Ranibizumab Versus Bevaci-zumab to Treat Neovascular Age-Related Macular Degeneration: One-Year Findings from the IVAN Randomized Trial”, Ophthalmology 119, no. 7 (2012): 1399–1411; U. Chakravarthy, et al., “Alternative Treatments to Inhibit VEGF in Age-Related Choroidal Neovascularisation: 2-year Findings of the IVAN Randomised Controlled Trial”, Lancet 382, no. 9900 (2013): 1258-1267.CrossRefGoogle Scholar
Verteporfin Roundtable, supra note 3.Google Scholar
Mass Eye and Ear Infirmary v. QLT Phototherapeutics, Inc., in 552, s. Cir., Editor. 2009, F.3d. p. 47, 57.Google Scholar
Adams, J. U., “Building the Bridge from Bench to Bedside”, Nature Reviews Drug Discovery 7, no. 6 (2008): 463–464.CrossRefGoogle Scholar
Id.Google Scholar
Mazzucato, M., “Mission-Oriented Innovation Policy: Challenges and Opportunites”, Industrial and Corporate Change 27, no. 5 (2018): 803–815.CrossRefGoogle Scholar